Eli Lilly and Company (LLY): Price and Financial Metrics


Eli Lilly and Company (LLY)

Today's Latest Price: $169.13 USD

2.38 (1.43%)

Updated Jul 8 4:10pm

Add LLY to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 213 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

LLY Stock Summary

  • LLY has a higher market value than 99.08% of US stocks; more precisely, its current market capitalization is $159,622,015,267.
  • The capital turnover (annual revenue relative to shareholder's equity) for LLY is 7.5 -- better than 94.87% of US stocks.
  • LLY's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 96.41% of US stocks.
  • If you're looking for stocks that are quantitatively similar to ELI LILLY & Co, a group of peers worth examining would be AMGN, NVO, ORCL, AZN, and ABT.
  • Visit LLY's SEC page to see the company's official filings. To visit the company's web site, go to www.lilly.com.
LLY Daily Price Range
LLY 52-Week Price Range

LLY Stock Price Chart Technical Analysis Charts


LLY Price/Volume Stats

Current price $169.13 52-week high $169.82
Prev. close $166.75 52-week low $101.36
Day low $166.84 Volume 2,782,025
Day high $169.82 Avg. volume 4,273,688
50-day MA $155.93 Dividend yield 1.78%
200-day MA $135.56 Market Cap 161.76B

Eli Lilly and Company (LLY) Company Bio


Eli Lilly discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. The company was founded in 1876 and is based in Indianapolis, Indiana.


LLY Latest News Stream


Event/TimeNews Detail
Loading, please wait...

LLY Latest Social Stream


Loading social stream, please wait...

View Full LLY Social Stream

Latest LLY News From Around the Web

Below are the latest news stories about ELI LILLY & Co that investors may wish to consider to help them evaluate LLY as an investment opportunity.

Sermonix teams up with Lilly in study of doublet therapy in type of breast cancer

Eli Lilly ([[LLY]] +1.3%) will collaborate with privately held Sermonix in an open-label Phase 2 clinical trial, ELAINE 2, evaluating the combination of Verzenio (abemaciclib) and the latter's lead drug lasofoxifene in pre- and postmenopausal women with locally advanced/metastatic ER+/HER2- breast cancer and an ESR1 mutation. Enrollment should launch this...

Seeking Alpha | July 8, 2020

Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know

Eli Lilly (LLY) closed the most recent trading day at $169.13, moving +1.43% from the previous trading session.

Yahoo | July 8, 2020

Immunomedics: A Solid Cancer Research Play

The company has a strong pipeline of antibody-drug conjugates Continue reading...

Yahoo | July 8, 2020

Biogen Shares Surge On FDA Application For Alzheimer's Treatment

Nine months after reviving trials of a key Alzheimer's treatment, Biogen has submitted an application for a 'priority review' to the Food & Drug Administration.

Yahoo | July 8, 2020

Why These 3 Pharma Stocks Are Outplaying 90% Of The Stock Market

Pharmaceutical stocks dipped by a single-digit percentage in the first six months of 2020, trailing their biotech brethren. Still, there are standout companies in the group.

Yahoo | July 8, 2020

Read More 'LLY' Stories Here

LLY Price Returns

1-mo 13.35%
3-mo 16.60%
6-mo 23.77%
1-year 52.77%
3-year 120.36%
5-year 116.33%
YTD 29.96%
2019 16.14%
2018 40.45%
2017 17.83%
2016 -10.37%
2015 25.39%

LLY Dividends

Ex-Dividend DateTypePayout AmountChange
Loading, please wait...
View Full LLY Dividend History

Continue Researching LLY

Want to see what other sources are saying about ELI LILLY & Co's financials and stock price? Try the links below:

ELI LILLY & Co (LLY) Stock Price | Nasdaq
ELI LILLY & Co (LLY) Stock Quote, History and News - Yahoo Finance
ELI LILLY & Co (LLY) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9558 seconds.